Federal Register Notice: FDA is seeking public comment on the proposed collection of information on sponsor requests for fast track designation of investigational new drugs (INDs) and new drug approvals or biological licenses as provided in the guidance for industry on fast track drug development programs. Comments should be submitted by 2/11. To view this notice, click here.
